Neurocrine Biosciences, Inc. Common Stock (NASDAQ: NBIX) last traded at $141.34, down 0.77% on the session. The quote above updates while this page is open; the figures below are drawn from Neurocrine Biosciences, Inc. Common Stock’s own filings and are restated only when a new one is published.
Neurocrine Biosciences, Inc. Common Stock trades on NASDAQ under the ticker NBIX. Its market capitalisation is $14.37 billion.
Valuation measures for Neurocrine Biosciences, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $14.37B |
|---|---|
| Enterprise value | $15.70B |
| P/E ratio | 20.69 |
| Price / sales | 4.26 |
| Price / book | 3.89 |
| Beta |
| 0.64 |
Trailing-twelve-month figures tagged in Neurocrine Biosciences, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $3.37B |
|---|---|
| Net income (TTM) | $705.50M |
| EPS (TTM) | $6.83 |
| Operating margin | 23.56% |
| Return on equity | 19.10% |
| Cash | $332.40M |
Range and volume for NBIX over the past 52 weeks.
| 52-week high | $186.12 |
|---|---|
| 52-week low | $122.14 |
| Volume | 211.8K |
| Average volume | 1.28M |
| Previous close | $142.44 |
Invest a chosen dollar amount in Neurocrine Biosciences, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell NBIX.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.